Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q2 FY19 results · Jul–Sep 2018
Sun Pharma Advanced Research Company reported revenue from operations of ₹61.35 crore and net loss of ₹2.58 crore for Q2 FY19 (Jul–Sep 2018), on a standalone basis.
| Item | Q2 FY19 | Q2 FY18 | YoY | Q1 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 61.35 | — | — | 16.81 | +265.0% |
| Other income | 4.57 | — | — | 1.23 | +271.5% |
| Total income | 65.92 | — | — | 18.04 | +265.4% |
| Profit before tax | (2.58) | — | — | (64.48) | Loss narrowed |
| Net profit for the period | (2.58) | — | — | (64.48) | Loss narrowed |
| EPS, basic (₹) | (0.10) | — | — | (2.57) | not comparable |
| Net margin (%) | -4.2 | — | -383.6 |
Standalone
- Filed with BSE
- 30 Oct 2018, 18:30 IST
- Board meeting
- 29 Oct 2018
- Period
- 01 Jul 2018 to 30 Sep 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE